CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade BridgeBio Pharma, Inc. - BBIO CFD

26.42
1.07%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon: 14:30 - 21:00

Tue: 14:30 - 18:00

Thu - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.13
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023374 %
Charges from full value of position ($-4.44)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023374%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001151 %
Charges from full value of position ($0.22)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001151%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 26.14
Open 26.01
1-Year Change -35.1%
Day's Range 26.01 - 26.77
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 20, 2024 26.42 0.45 1.73% 25.97 26.83 25.95
Dec 19, 2024 26.14 0.12 0.46% 26.02 26.52 25.29
Dec 18, 2024 25.93 -1.82 -6.56% 27.75 28.08 25.45
Dec 17, 2024 27.76 0.51 1.87% 27.25 27.89 27.11
Dec 16, 2024 27.65 0.29 1.06% 27.36 28.08 27.36
Dec 13, 2024 27.43 -0.18 -0.65% 27.61 28.09 26.96
Dec 12, 2024 27.61 -1.03 -3.60% 28.64 29.03 27.39
Dec 11, 2024 28.92 -0.21 -0.72% 29.13 29.57 28.88
Dec 10, 2024 28.99 -0.26 -0.89% 29.25 29.90 28.55
Dec 9, 2024 29.44 0.88 3.08% 28.56 29.47 28.28
Dec 6, 2024 28.71 2.12 7.97% 26.59 29.10 26.49
Dec 5, 2024 26.61 -0.07 -0.26% 26.68 27.15 26.29
Dec 4, 2024 27.01 0.66 2.50% 26.35 27.72 26.16
Dec 3, 2024 26.52 0.24 0.91% 26.28 26.99 26.27
Dec 2, 2024 26.53 -0.18 -0.67% 26.71 27.06 26.10
Nov 29, 2024 26.96 -0.63 -2.28% 27.59 27.95 26.96
Nov 27, 2024 27.41 1.03 3.90% 26.38 28.11 26.18
Nov 26, 2024 26.38 -0.49 -1.82% 26.87 27.73 25.47
Nov 25, 2024 27.13 -1.36 -4.77% 28.49 30.38 26.81
Nov 22, 2024 23.36 0.31 1.34% 23.05 23.58 22.40

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

BridgeBio Pharma, Inc. Company profile

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; the University of California, San Diego; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; UC San Francisco; the Canadian Glycomics Network (GlycoNet); the University of California; Columbia University; Mount Sinai; and Helsinn Group, as well as a clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398. It also has a research collaboration and option agreement with Unnatural Products Inc. to target rare diseases with potential oncology applications. The company was founded in 2015 and is headquartered in Palo Alto, California.
Industry: Biopharmaceuticals

3160 Porter Dr.
Suite 250
PALO ALTO
CALIFORNIA 94304
US

People also watch

BTC/USD

95,078.70 Price
-2.170% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

ETH/USD

3,307.59 Price
-0.910% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

XRP/USD

2.19 Price
-2.640% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01091

US100

21,392.60 Price
+0.620% 1D Chg, %
Long position overnight fee -0.0234%
Short position overnight fee 0.0012%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading